These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16258942)

  • 41. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
    Kumar P; Kumar A
    Behav Brain Res; 2010 Jan; 206(1):38-46. PubMed ID: 19716383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diffusion-weighted imaging in Huntington's disease.
    Seppi K; Schocke MF; Mair KJ; Esterhammer R; Weirich-Schwaiger H; Utermann B; Egger K; Brenneis C; Granata R; Boesch S; Poewe W; Wenning GK
    Mov Disord; 2006 Jul; 21(7):1043-7. PubMed ID: 16570300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
    Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The origin of halitosis in cystinotic patients due to cysteamine treatment.
    Besouw M; Blom H; Tangerman A; de Graaf-Hess A; Levtchenko E
    Mol Genet Metab; 2007 Jul; 91(3):228-33. PubMed ID: 17513151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of CAG repeat length on psychiatric disorders in Huntington's disease.
    Vassos E; Panas M; Kladi A; Vassilopoulos D
    J Psychiatr Res; 2008 Jun; 42(7):544-9. PubMed ID: 17610899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain.
    Curtis MA; Faull RL; Glass M
    J Chem Neuroanat; 2006 Apr; 31(3):210-5. PubMed ID: 16533591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
    Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
    Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
    Dhir A; Akula KK; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice.
    Shieh CH; Hong CJ; Huang YH; Tsai SJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1590-4. PubMed ID: 18582526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Behavioural problems in Huntington's disease using the Problem Behaviours Assessment.
    Kingma EM; van Duijn E; Timman R; van der Mast RC; Roos RA
    Gen Hosp Psychiatry; 2008; 30(2):155-61. PubMed ID: 18291297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The capacity of attention and simultaneous perception of objects: a group study of Huntington's disease patients.
    Finke K; Schneider WX; Redel P; Dose M; Kerkhoff G; Müller HJ; Bublak P
    Neuropsychologia; 2007 Nov; 45(14):3272-84. PubMed ID: 17681560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute effects of scopolamine in Huntington's disease.
    Nutt JG; Morgan NT
    Adv Neurol; 1983; 37():291-7. PubMed ID: 6222635
    [No Abstract]   [Full Text] [Related]  

  • 58. An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis.
    Devereux G; Steele S; Griffiths K; Devlin E; Fraser-Pitt D; Cotton S; Norrie J; Chrystyn H; O'Neil D
    Clin Drug Investig; 2016 Aug; 36(8):605-12. PubMed ID: 27153825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Kinetic study of radiolesions of the testis in rats. Abs5nce of the protective effect of cysteamine].
    Maldague P; Maisin H
    Pathol Eur; 1966; 1(1):67-84. PubMed ID: 5989465
    [No Abstract]   [Full Text] [Related]  

  • 60. Huntington's disease: clinical effects of a short-term treatment with pimozide.
    Arena R; Iudice A; Virgili P; Moretti P; Menchetti G
    Adv Biochem Psychopharmacol; 1980; 24():573-5. PubMed ID: 6447434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.